As European markets navigate a complex landscape of monetary policy decisions and mixed economic signals, investors are keenly assessing opportunities for value amidst the fluctuations. In this context, identifying stocks that are trading below their intrinsic value can be particularly appealing, as they may offer potential upside when market conditions stabilize.
Below we spotlight a couple of our favorites from our exclusive screener.
Overview: Línea Directa Aseguradora, S.A., Compañía de Seguros y Reaseguros operates in the insurance and reinsurance sectors in Spain and Portugal, with a market capitalization of approximately €1.38 billion.
Operations: Línea Directa’s revenue is primarily derived from its Auto segment, which accounts for €866.19 million, followed by Home at €164.38 million and Health at €37.78 million.
Estimated Discount To Fair Value: 24.7%
Línea Directa Aseguradora’s recent earnings report shows a significant increase in net income to €43.77 million for the first half of 2025, up from €25.42 million the previous year, with basic earnings per share doubling to €0.04. Despite an unstable dividend history, the stock trades at 24.7% below its estimated fair value and is highly undervalued based on discounted cash flow analysis, making it a potential opportunity for investors focusing on cash flows.
BME:LDA Discounted Cash Flow as at Sep 2025
Overview: Cogelec SA designs, manufactures, and sells access control and wireless intercom systems both in France and internationally, with a market capitalization of €238.05 million.
Operations: Cogelec generates its revenue by providing access control and wireless intercom solutions to both domestic and international markets.
Estimated Discount To Fair Value: 25.5%
Cogelec is trading 25.5% below its estimated fair value of €38.53, presenting a potential opportunity for investors focusing on cash flows. Despite a decline in net income to €2.48 million for the first half of 2025, Cogelec’s earnings are forecasted to grow significantly over the next three years, outpacing the French market. The recent exclusive collaboration with Amazon Key across five European countries could enhance revenue growth prospects and strengthen its market position in wireless access solutions.
ENXTPA:ALLEC Discounted Cash Flow as at Sep 2025
Overview: BioGaia AB (publ) is a healthcare company that develops, manufactures, markets, and sells probiotic products for gut, oral, and immune health across various regions including Europe and the United States, with a market cap of SEK11.07 billion.
Operations: The company’s revenue is primarily derived from its Pediatrics segment, generating SEK1.08 billion, followed by Adult Health at SEK352.62 million.
Estimated Discount To Fair Value: 34.7%
BioGaia is trading at SEK109.4, significantly below its estimated fair value of SEK167.51, suggesting potential undervaluation based on cash flows. Despite a drop in profit margins from 29.3% to 19.9%, earnings are expected to grow significantly over the next three years, surpassing Swedish market averages. Recent strategic moves include direct distribution in Germany and Austria and expansion into skin health via BioGaia New Sciences AB, potentially enhancing revenue streams and market presence.
OM:BIOG B Discounted Cash Flow as at Sep 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BME:LDA ENXTPA:ALLEC and OM:BIOG B.
This article was originally published by Simply Wall St.
